Loading...

David Wofsy, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address533 Parnassus Avenue
San Francisco CA 94117
Phone415-502-2397
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine
    Collapse Awards and Honors
    American College of Rheumatology2012Master of the American College of Rheumatology
    New York Academy of Medicine2011Paul Klemperer Award and Medal
    Arthritis Foundation2007Lee C. Howley Sr. Prize
    Arthritis Foundation2001Arthritis Hero Award
    American College of Rheumatology1999Edmund L. Dubois Award for Outstanding Research in SLE

    Collapse Overview 
    Collapse Overview
    Dr. Wofsy received his undergraduate degree from Harvard (1968), his MD from the University of California, San Diego (1974), and his medical residency training and rheumatology fellowship training from the University of California, San Francisco. He joined the UCSF faculty in 1980. He currently Professor of Medicine and Microbiology/Immunology at UCSF. Dr. Wofsy also serves as Associate Dean for Admissions for the UCSF School of Medicine. He has served on numerous NIH study sections, and on the Arthritis Advisory Committee of the Food and Drug Administration. Dr. Wofsy is a past-President of the American College of Rheumatology.

    Dr. Wofsy's research program is devoted to the development of novel therapies for autoimmune diseases, particularly systemic lupus erythematosus (SLE). For many years, his research focused on the cellular and molecular mechanisms that lead to autoimmunity in murine models for SLE. These therapies are designed to block pathologic immune responses without damaging the entire immune system. One of the therapies that was pioneered by Dr. Wofsy's group involves the B7 family of molecules on antigen-presenting cells (APC). These molecules play a pivotal role in the generation of T-cell help. Specifically, the interaction of B7 molecules on APC with their ligand (designated CD28) on T cells provides an important signal for T-cell activation. Dr. Wofsy first showed that selective inhibition of the B7-CD28 interaction retards autoimmunity in murine lupus. He subsequently showed that this beneficial effect could be enhanced substantially in two ways: (i) by combining blockade of B7-CD28 with blockade of other receptor-ligand pairs (CD40-CD40L) on the surface of T cells and APC; and (ii) by combining blockade of B7-CD28 with cyclophosphamide therapy. In each case, combination therapy provided a prolonged benefit without sustained generalized immune suppression. This work laid the foundation for translational studies that resulted in FDA approval of a new treatment for rheumatoid arthritis. Dr.Wofsy's current research is focused on establishing whether this therapy can be life-saving in people with kidney disease due to SLE.


    Collapse Research 
    Collapse Research Activities and Funding
    PEARL: Pathway Exploration and Analysis in Renal Lupus
    NIH UH2AR067688Sep 24, 2014 - May 31, 2019
    Role: Principal Investigator
    Autoimmunity Center of Excellence Clinical Research Program
    NIH/NIAID UM1AI110498May 1, 2014 - Apr 30, 2019
    Role: Principal Investigator
    Autoimmunity Center of Excellence
    NIH/NIAID U19AI056388Sep 30, 2003 - Apr 30, 2014
    Role: Principal Investigator
    NEW STRATEGIES FOR USING ANTI-L3T4 TO STUDY MURINE LUPUS
    NIH/NIAID R01AI025578May 1, 1988 - Apr 30, 1991
    Role: Principal Investigator
    Academic Rheumatology and Clinical Immunology
    NIH/NIAMS T32AR007304Jul 1, 1978 - Apr 30, 2020
    Role: Co-Principal Investigator
    MULTIPURPOSE ARTHRITIS AND MUSCULOSKELETAL DISEASES CTR
    NIH/NIAMS P60AR020684Sep 15, 1977 - Dec 31, 2003
    Role: Principal Investigator
    U.C.S.F. MULTIPURPOSE ARTHRITIS CENTER
    NIH P60AM020684Sep 15, 1977 - Dec 31, 1988
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000079Dec 1, 1974 - Mar 31, 2009
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 Mar 21. PMID: 29563108.
      View in: PubMed
    2. Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools? Acad Med. 2018 Mar 20. PMID: 29561273.
      View in: PubMed
    3. Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. Arthritis Care Res (Hoboken). 2018 Apr; 70(4):571-581. PMID: 28692774.
      View in: PubMed
    4. Jerant A, Henderson MC, Griffin E, Rainwater JA, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. Reliability of Multiple Mini-Interviews and traditional interviews within and between institutions: a study of five California medical schools. BMC Med Educ. 2017 Nov 06; 17(1):190. PMID: 29110662.
      View in: PubMed
    5. Henderson MC, Kelly CJ, Griffin E, Hall TR, Jerant A, Peterson EM, Rainwater JA, Sousa FJ, Wofsy D, Franks P. Medical School Applicant Characteristics Associated With Performance in Multiple Mini-Interviews Versus Traditional Interviews: A Multi-Institutional Study. Acad Med. 2017 Oct 31. PMID: 29095170.
      View in: PubMed
    6. Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D. Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. Lupus Sci Med. 2017; 4(1):e000229. PMID: 29214037.
      View in: PubMed
    7. Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Arthritis Rheumatol. 2017 01; 69(1):122-130. PMID: 27390168.
      View in: PubMed
    8. Wofsy D. In memoriam: Ephraim P. Engleman, MD, 1911-2015. Arthritis Rheumatol. 2015 Nov; 67(11):2795-6. PMID: 26508466.
      View in: PubMed
    9. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med. 2015; 2(1):e000089. PMID: 26023331; PMCID: PMC4442174.
    10. Wofsy D, Diamond B, Houssiau FA. Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America. Arthritis Rheumatol. 2015 May; 67(5):1144-6. PMID: 25779381; PMCID: PMC4523131.
    11. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015 Nov; 74(11):2006-15. PMID: 24951103; PMCID: PMC4680140.
    12. Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 2013 Jun; 65(6):1586-91. PMID: 23529285.
      View in: PubMed
    13. Wofsy D. Recent progress in conventional and biologic therapy for systemic lupus erythematosus. Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii66-8. PMID: 23253930.
      View in: PubMed
    14. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012 Nov; 64(11):3660-5. PMID: 22806274.
      View in: PubMed
    15. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17; 365(20):1886-95. PMID: 22087680.
      View in: PubMed
    16. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011 May; 38(5):846-54. PMID: 21285160.
      View in: PubMed
    17. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011 Mar; 63(3):351-7. PMID: 21080348.
      View in: PubMed
    18. Papadakis MA, Wofsy D. Plagiarism on personal statements: a disturbing symptom of a broader trend. Ann Intern Med. 2010 Jul 20; 153(2):128-9. PMID: 20643994.
      View in: PubMed
    19. Dall'Era M, Wofsy D. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Nat Rev Rheumatol. 2010 Mar; 6(3):124-5. PMID: 20197774.
      View in: PubMed
    20. Dall'Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Discov Med. 2010 Jan; 9(44):20-3. PMID: 20102681.
      View in: PubMed
    21. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010 Jan; 62(1):211-21. PMID: 20039429.
      View in: PubMed
    22. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010 Jan; 49(1):128-40. PMID: 19933596; PMCID: PMC2789586.
    23. Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009 Oct; 5(10):560-5. PMID: 19798031; PMCID: PMC3086064.
    24. Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol. 2009 Jun; 5(6):348-51. PMID: 19491915.
      View in: PubMed
    25. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May; 20(5):1103-12. PMID: 19369404; PMCID: PMC2678035.
    26. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH, Thomson GE, Wofsy D. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009 Apr 01; 301(13):1367-72. PMID: 19336712.
      View in: PubMed
    27. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum. 2009 Mar 15; 61(3):370-7. PMID: 19248127; PMCID: PMC2748348.
    28. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50. PMID: 18050206.
      View in: PubMed
    29. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus. 2007; 16(12):972-80. PMID: 18042591.
      View in: PubMed
    30. Dall'Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol. 2006 Sep; 18(5):476-80. PMID: 16896285.
      View in: PubMed
    31. Daikh DI, Gillis J, Wofsy D. Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases. Arthritis Rheum. 2006 Apr 15; 55(2):322-4. PMID: 16583382.
      View in: PubMed
    32. Wofsy D. Living in a different world. Arthritis Rheum. 2005 Feb; 52(2):395-401. PMID: 15692996.
      View in: PubMed
    33. Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA4Ig takes on lupus. Lupus. 2005; 14(3):197-203. PMID: 15807196.
      View in: PubMed
    34. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8. PMID: 12483729.
      View in: PubMed
    35. Wofsy D, Daikh DI. Treatment of autoimmune diseases by inhibition of T-cell costimulation. Mod Rheumatol. 2002 Mar; 12(1):1-4. PMID: 24383824.
      View in: PubMed
    36. Diamond B, Bluestone J, Wofsy D. The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Arthritis Rheum. 2001 Aug; 44(8):1730-5. PMID: 11508422.
      View in: PubMed
    37. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001 Mar 01; 166(5):2913-6. PMID: 11207238.
      View in: PubMed
    38. Daikh DI, Wofsy D. Treatment of autoimmunity by inhibition of T cell costimulation. Adv Exp Med Biol. 2001; 490:113-7. PMID: 11505969.
      View in: PubMed
    39. Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001 Jan; 28(1):95-101. PMID: 11196549.
      View in: PubMed
    40. Daikh DI, Wofsy D. Effects of anti-B7 monoclonal antibodies on humoral immune responses. J Autoimmun. 1999 Mar; 12(2):101-8. PMID: 10047430.
      View in: PubMed
    41. Daikh DI, Wofsy D. On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases. Transplant Proc. 1998 Dec; 30(8):4027-8. PMID: 9865285.
      View in: PubMed
    42. Wofsy D, Daikh DI. Opportunities for future biological therapy in SLE. Baillieres Clin Rheumatol. 1998 Aug; 12(3):529-41. PMID: 9890111.
      View in: PubMed
    43. Chesnutt MS, Finck BK, Killeen N, Connolly MK, Goodman H, Wofsy D. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice. Clin Immunol Immunopathol. 1998 Apr; 87(1):23-32. PMID: 9576007.
      View in: PubMed
    44. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997 Oct 01; 159(7):3104-8. PMID: 9317105.
      View in: PubMed
    45. Daikh D, Wofsy D, Imboden JB. The CD28-B7 costimulatory pathway and its role in autoimmune disease. J Leukoc Biol. 1997 Aug; 62(2):156-62. PMID: 9261329.
      View in: PubMed
    46. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994 Aug 26; 265(5176):1225-7. PMID: 7520604.
      View in: PubMed
    47. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994 Aug; 94(2):585-91. PMID: 8040314; PMCID: PMC296134.
    48. Connolly MK, Kitchens EA, Chan B, Jardieu P, Wofsy D. Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy. Clin Immunol Immunopathol. 1994 Aug; 72(2):198-203. PMID: 8050193.
      View in: PubMed
    49. Connolly K, Roubinian JR, Wofsy D. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol. 1992 Nov 01; 149(9):3083-8. PMID: 1357036.
      View in: PubMed
    50. Wofsy D, Carteron NL. CD4 antibody therapy in systemic lupus erythematosus. Semin Immunol. 1990 Nov; 2(6):419-25. PMID: 2104279.
      View in: PubMed
    51. Carteron NL, Wofsy D, Schimenti C, Ermak TH. F(ab')2 anti-CD4 and intact anti-CD4 monoclonal antibodies inhibit the accumulation of CD4+ T cells, CD8+ T cells, and B cells in the kidneys of lupus-prone NZB/NZW mice. Clin Immunol Immunopathol. 1990 Sep; 56(3):373-83. PMID: 1975226.
      View in: PubMed
    52. Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-alpha on immune function. J Immunol. 1990 Mar 01; 144(5):1753-8. PMID: 2307839.
      View in: PubMed
    53. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989 Sep; 52(3):421-34. PMID: 2758698.
      View in: PubMed
    54. Erlich KS, Wofsy D, Dix RD, Mills J. Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis. Clin Immunol Immunopathol. 1989 Aug; 52(2):190-201. PMID: 2525439.
      View in: PubMed
    55. Carteron NL, Schimenti CL, Wofsy D. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. J Immunol. 1989 Mar 01; 142(5):1470-5. PMID: 2521880.
      View in: PubMed
    56. Wofsy D, Chiang NY, Greenspan JS, Ermak TH. Treatment of murine lupus with monoclonal antibody to L3T4. I. Effects on the distribution and function of lymphocyte subsets and on the histopathology of autoimmune disease. J Autoimmun. 1988 Oct; 1(5):415-31. PMID: 3267085.
      View in: PubMed
    57. Wofsy D. The role of Lyt-2+ T cells in the regulation of autoimmunity in murine lupus. J Autoimmun. 1988 Apr; 1(2):207-17. PMID: 2978113.
      View in: PubMed
    58. Carteron NL, Wofsy D, Seaman WE. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol. 1988 Feb 01; 140(3):713-6. PMID: 2448372.
      View in: PubMed
    59. Wofsy D. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. J Immunol. 1986 Jun 15; 136(12):4554-60. PMID: 3086436.
      View in: PubMed
    60. Wofsy D, Ledbetter JA, Hendler PL, Seaman WE. Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol. 1985 Feb; 134(2):852-7. PMID: 3871218.
      View in: PubMed
    61. Wofsy D. [Not Available]. Immunol Today. 1984 Jul; 5(7):191-2. PMID: 25289950.
      View in: PubMed
    62. Wofsy D. Hormones, handedness, and autoimmunity. Immunol Today. 1984 Jun; 5(6):169-70. PMID: 25289744.
      View in: PubMed
    63. Talal N, Dauphinee MJ, Wofsy D. Interleukin-2 deficiency, genes, and systemic lupus erythematosus. Arthritis Rheum. 1982 Jul; 25(7):838-42. PMID: 6285934.
      View in: PubMed